Dechra, a veterinary products firm, agreed to acquire Piedmont Animal Health, a provider of pharmaceutical services, for $210m. The deal accelerates the provision of innovative solutions to veterinarians and pet owners in areas of unmet or under serviced medical needs. Novel pipeline is complementary to Dechra's existing CAP portfolio, provide the opportunity to significantly strengthen Dechra's presence in key therapeutic areas of dermatology, pain management and anti-infectives. While initial product registrations will be focused on the key North American and European markets, there is the opportunity over time to register products in international markets; and adds strength and expertise to the Company's existing product development resource.